Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-11-26 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER
Foreign Filer Report
2025-11-26 English
Imfinzi approved in US for early gastric cancer
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the US FDA approval of 'Imfinzi' for the treatment of gastric and gastroesophageal cancers. It details the clinical trial results (MATTERHORN Phase III), provides quotes from company executives and medical professionals, and explains the regulatory context. This is a standard corporate announcement regarding product development and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general regulatory/corporate announcement that does not fit into specific financial reporting categories like 10-K or IR.
2025-11-26 English
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND
Foreign Filer Report
2025-11-24 English
AstraZeneca manufacturing investment in Maryland
Regulatory Filings Classification · 1% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding a $2 billion capital investment in manufacturing facilities in Maryland. It details corporate strategy, expansion plans, and economic impact. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a general corporate announcement distributed via a regulatory channel, it is classified as a Regulatory Filing (RNS).
2025-11-24 English
KOSELUGO (SELUMETINIB) APPROVED IN THE US
Foreign Filer Report
2025-11-20 English
Koselugo (selumetinib) approved in the US
Regulatory Filings Classification · 1% confidence The document is an official announcement from AstraZeneca regarding the FDA approval of their drug 'Koselugo'. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it contains detailed information about clinical trials and drug efficacy, it is a corporate press release/announcement rather than a formal financial report, legal proceeding, or investor presentation. As it does not fit into specific categories like 'Earnings Release' (which focuses on financial results) or 'Report Publication Announcement' (which is a short notice about another document), it falls under the 'Regulatory Filings' (RNS) category as the standard fallback for general corporate regulatory announcements.
2025-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.